impact of laughter yoga on the stress of cancer patients before chemotherapy

Cancer is usually accompanied by considerable stress for the sufferer, and the stress has destructive effects on Chemotherapy treatment process. Therefore, the current research deals with the effect of yoga laughter on the cancer patients' stress before chemotherapy. In this research, as the first step, 37 cancer sufferers, who had been hospitalized in Shohada Tajrish Hospital [Behnam Daneshpoor Charity Organization] and had the requirements necessary for being taken as research samples, were selected for data collection. The mentioned patients were classified randomly in experimental and control groups. Collected data were analyzed by the multi-variable covariance analysis test. The results show there is a meaningful difference in the stress average before and after interference in the test group [p<0.05]. Laughter yoga can decrease the stress in cancer sufferers before chemotherapy

Relation between HER-2 gene expression and gleason score in patients with Prostate Cancer

HER-2 is a proto-oncogene of the tyrosine kinase receptor family on chromosome 17. Overexpression of this gene affects the growth and prognosis of some tumors. This study was performed to evaluate the expression of the HER-2 gene in patients with prostate cancer and its relation with the Gleason score. Pathology specimens of all men with prostate cancer who had undergone radical prostatectomy without any supportive treatment were studied. The Gleason scores of the specimens and the expression of HER-2 gene were examined. The expression of HER-2 was scored between zero and 3+ in accordance with the Hercep Test method. Patients with scores of 2+ and 3+ were considered to be positive for HER-2 overexpression. Of 150 cancerous prostate specimens evaluated, 20 [13.3%] were positive for HER-2 gene overexpression. A weakly positive HeR-2 overexpression [2+] was seen in 15 of them [75%] and the remaining 5 [25%] were strongly positive. The Gleason score was not different between the HER-2-positive and HER-2-negative patients [P=.08]. Fourteen out of 97 patients [14.4%] with a Gleason score less than 7 and 6 out of 53 [11.3%] with scores of 7 or greater were positive for HER-2 overexpression. The frequency of HER-2 gene overexpression is not very high in our patients with prostate cancer, and we failed to show any association of HER-2 expression and the Gleason score